Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 11/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 9/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 9/20 | 1.00 |
| ▸ | MET | P08581 | 7/20 | 1.00 |
| ▸ | SRC | P12931 | 6/20 | 1.00 |
| ▸ | LCK | P06239 | 4/20 | 1.00 |
| ▸ | YES1 | P07947 | 4/20 | 1.00 |
| ▸ | CDK2 | P24941 | 2/20 | 1.00 |
| ▸ | PTK2B | Q14289 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | KIT | P10721 | 2/20 | 1.00 |
| ▸ | EGFR | P00533 | 2/20 | 1.00 |
| ▸ | ALK | Q9UM73 | 2/20 | 1.00 |
| ▸ | PLK4 | O00444 | 1/20 | 1.00 |
| ▸ | RIOK3 | O14730 | 1/20 | 1.00 |
| ▸ | CASK | O14936 | 1/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 1.00 |
| ▸ | DCLK1 | O15075 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pha-665752 SCHEMBL93656 | 1.00 | KDR (1.00) | KDRFGFR1PDGFRBMETSRC | |
| Pha-665752 SCHEMBL93657 | 1.00 | KDR (1.00) | KDRFGFR1PDGFRBMETSRC | |
| Pha-665752 SCHEMBL93655 | 1.00 | KDR (1.00) | KDRFGFR1PDGFRBMETSRC | |
| Pha-665752 SCHEMBL140412 | 1.00 | KDR (1.00) | KDRFGFR1PDGFRBMETSRC | |
| Pha-665752 SCHEMBL93654 | 1.00 | KDR (1.00) | KDRFGFR1PDGFRBMETSRC | |
| Pha-665752 SCHEMBL15639801 | 0.99 | KDR (0.99) | KDRFGFR1PDGFRBMETSRC | |
| Pha-665752 SCHEMBL15639803 | 0.99 | KDR (0.99) | KDRFGFR1PDGFRBMETSRC | |
| SCHEMBL23691031 | 0.97 | KDR (0.94) | KDRFGFR1PDGFRBMETSRC | |
| SCHEMBL143795 | 0.96 | KDR (0.93) | KDRFGFR1PDGFRBMETSRC | |
| SCHEMBL147331 | 0.95 | KDR (0.91) | KDRFGFR1PDGFRBMETSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 483 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4640238-A1 | THERAPEUTIC AGENT FOR PULMONARY DISEASE, HEPATIC DISEASE OR RENAL DISEASE, WHICH CONTAINS PGAM-CHK1 BINDING INHIBITOR | Kyoto University (JP) | 2025-10-29 | — | — | EP | claimed |
| EP-4633630-A1 | TREATMENT OF CANCER RESISTANT TO EGFR TKI USING C-MET INHIBITOR | Apollomics Inc. (US) | 2025-10-22 | — | — | EP | claimed |
| EP-4615869-A1 | COMBINATION THERAPY COMPRISING BISPECIFIC ANTIBODIES COMPRISING AN NRP1 BINDING DOMAIN | Pinetree Therapeutics, Inc. (US) | 2025-09-17 | — | — | EP | claimed |
| US-20250270651-A1 | DETECTION OF MET AMPLIFICATION TO PREDICT RESPONSIVENESS OF CANCER TO DRUGS | THE GENERAL HOSPITAL CORPORATION (US) | 2025-08-28 | — | — | US | claimed |
| US-20250003952-A1 | SENOLYTIC DRUG SCREENING METHOD AND SENOLYTIC DRUG | KYOTO UNIVERSITY (JP) | 2025-01-02 | — | — | US | claimed |
| US-20240398801-A1 | TREATMENT OF LEUKEMIA BASED ON LEUKEMIA HIERARCHY IN A PATIENT | UNIVERSITY HEALTH NETWORK (CA) | 2024-12-05 | — | — | US | claimed |
| EP-4423302-A2 | NOVEL KINASE FUSIONS DETECTED BY LIQUID BIOPSY | Foundation Medicine, Inc. (US) | 2024-09-04 | — | — | EP | claimed |
| CN-118414439-A | Novel kinase fusion by liquid biopsy | 基金会医学公司 | 2024-07-30 | — | — | CN | claimed |
| EP-4400117-A1 | SENOLYTIC DRUG SCREENING METHOD AND SENOLYTIC DRUG | Kyoto University (JP) | 2024-07-17 | — | — | EP | claimed |
| US-20240218453-A1 | DIAGNOSTIC AND TREATMENT OF CANCER USING C-MET INHIBITOR | APOLLOMICS INC. | 2024-07-04 | — | — | US | claimed |
| WO-2023050018-A1 | TREATMENT OF LEUKEMIA BASED ON LEUKEMIA HIERARCHY IN A PATIENT | UNIVERSITY HEALTH NETWORK (CA) | 2023-04-06 | — | — | WO | claimed |
| WO-2023038027-A1 | SENOLYTIC DRUG SCREENING METHOD AND SENOLYTIC DRUG | 国立大学法人京都大学 | 2023-03-16 | — | — | WO | claimed |
| US-11583544-B2 | Remote loading of sparingly water-soluble drugs into lipid vesicles | CELATOR PHARMACEUTICALS, INC. (US) | 2023-02-21 | — | — | US | claimed |
| US-20220412957-A1 | METHODS OF TREATING CANCER PATIENTS WITH RAS NODE OR RTK TARGETED THERAPEUTIC AGENTS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2022-12-29 | — | — | US | claimed |
| WO-2022226168-A1 | DIAGNOSTIC AND TREATMENT OF CANCER USING C-MET INHIBITOR | APOLLOMICS INC. (US) | 2022-10-27 | — | — | WO | claimed |
| EP-4073516-A1 | METHODS OF TREATING CANCER PATIENTS WITH RAS NODE OR RTK TARGETED THERAPEUTIC AGENTS | Celcuity Inc. (US) | 2022-10-19 | — | — | EP | claimed |
| US-20220252603-A1 | METHOD FOR TREATING CANCER PATIENTS USING C-MET INHIBITOR | APOLLOMICS INC. (HANGZHOU) (CN) | 2022-08-11 | — | — | US | claimed |
| CN-114599978-A | Methods of treating cancer patients using C-MET inhibitors | 浙江冠科美博生物科技有限公司 | 2022-06-07 | — | — | CN | claimed |
| EP-3980783-A1 | METHOD FOR TREATING CANCER PATIENTS USING C-MET INHIBITOR | Apollomics Inc. (Hangzhou) (CN) | 2022-04-13 | — | — | EP | claimed |
| EP-3964206-A1 | COMPOUNDS FOR THE TREATMENT OF COVID-19 | Dompe' Farmaceutici S.P.A. (IT) | 2022-03-09 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240218453-A1 | DIAGNOSTIC AND TREATMENT OF CANCER USING C-MET INHIBITOR | MET, METTL16, HGF | KDR 516/4885FGFR1 150/4885PDGFRB 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.